1. Home
  2. Companies
  3. AVE
  4. Material Events

Avecho Biotechnology (ASX:AVE) — Material Events

ASX:AVE · 13 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
Avecho Advances Phase III CBD Trial, Signs $4.8M Sandoz Licensing DealMedium
Avecho reports higher revenue and loss, advances Phase III CBD insomnia trial, signs Sandoz licensing deal, raises $2.5M for manufacturing
27 Feb 2026 ·Appendix 4E Preliminary Final Report ·85
Avecho Nears Key Milestone in CBD Insomnia Trial with $2.5M Boost and Patent WinsMedium
Avecho advances Phase III CBD insomnia trial, raises $2.5M, secures US and EU patent allowances
29 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·85
Avecho Surpasses Phase III Recruitment Target Ahead of June Interim AnalysisMedium
Avecho exceeds Phase III trial recruitment, interim analysis on track for June, commercial deal with Sandoz in Australia
29 Apr 2026 ·Quarterly Activities Report and Appendix 4C ·85
Avecho Secures Key US and European Patents for CBD Soft-Gel Ahead of Phase III MilestoneMedium
Avecho's CBD Soft-Gel Patents Allowed in US and Europe, Phase III Trial Progresses
3 Dec 2025 ·Patent Allowance and Clinical Trial Update ·85
Avecho Hits Key Milestone in Phase III CBD Insomnia Trial, Interim Results Due JuneMedium
Avecho completes recruitment for Phase III CBD insomnia trial interim analysis, results due June 2026
2 Mar 2026 ·ASX Announcement ·85
Avecho Completes Treatment Phase in Phase III Insomnia Trial Ahead of June Interim ReadoutMedium
Avecho completes treatment phase in Phase III insomnia trial, interim results due June 2026
21 May 2026 ·Clinical Trial Update ·85
Avecho Accelerates Phase III Trial, Eyes First OTC CBD Insomnia Product in AustraliaMedium
Avecho Accelerates Phase III Insomnia Trial, Targets First OTC CBD Product in Australia
30 July 2025 ·Quarterly Activities Report and Appendix 4C ·80
Avecho Secures $2.5M to Accelerate CBD Capsule CommercialisationMedium
Avecho raises $2.5M to fast-track CBD capsule manufacturing and Phase III trial progress
23 Oct 2025 ·Capital Raising ·80
Avecho Boosts Trial Momentum with $2.5M Raise Ahead of Key CBD Insomnia DataMedium
Avecho advances Phase III CBD insomnia trial, raises $2.5M to support TGA submission
31 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·75
Avecho Accelerates Phase III CBD Trial Recruitment Ahead of 2026 Interim AnalysisMedium
Avecho's Phase III CBD Insomnia Trial Recruitment Accelerates, Interim Analysis Expected in 2026
29 July 2025 ·Clinical Trial Update ·75
Avecho Nears Key Milestone in CBD Insomnia Trial RecruitmentMedium
Avecho nears completion of Phase III trial recruitment for CBD insomnia treatment, interim analysis expected H1 2026
18 Dec 2025 ·Clinical Trial Update ·75
Avecho Boosts Revenue but Loss Widens Amid $4.8M Sandoz Licensing DealMedium
Avecho reports increased loss despite revenue growth; secures $4.8M licensing deal with Sandoz for CBD insomnia treatment
28 Aug 2025 ·Appendix 4D Half-year report ·75
Avecho Raises $1.9 Million From Option Exercises Ahead of Phase III Interim ResultsMedium
Avecho raises $1.9 million from option exercises ahead of Phase III insomnia trial interim results
12 May 2026 ·Capital Raising ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.